About Vion

Vion Vision

We are committed to extending the lives and improving the quality of life of cancer patients worldwide by bringing innovative cancer treatments to market.

Incorporated in March 1992 to commercialize several discoveries made in the biomedical laboratories at Yale University, Vion has been a publicly traded company on NASDAQ (VION) since 1995. Vion has two anticancer compounds in human clinical testing.

Clinical Development

Two small molecules, Cloretazine® (VNP40101M) and Triapine®, are in human clinical trials. Cloretazine® (VNP40101M), a novel alkylating agent, is being evaluated for the treatment of acute myelogenous leukemia (AML) in a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition, clinical trials of Cloretazine® (VNP40101M) are underway in brain tumors in combination with temzolomide and in advanced hematologic malignancies in combination with hematopoietic cell transplantation. Our ribonucleotide reductase inhibitor Triapine® is being evaluated in clinical trials sponsored by the National Cancer Institute.